Zhang Zhijie, Chen Meng, Yu Ying, Pan Sisi, Liu Yong
Clinical Laboratory Department, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Department of Rheumatology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Infect Drug Resist. 2019 May 10;12:1209-1220. doi: 10.2147/IDR.S203121. eCollection 2019.
In order to understand the prevalence of and globally and provide the basis for rational use of antimicrobials in clinical settings, in vitro activity of tigecycline and comparative agents was evaluated against 3929 and 4043 isolates obtained from 150 centers globally between 2015 and 2017 as a part of the Tigecycline Evaluation and Surveillance Trial (TEST). Broth microdilution methods were performed to determine the minimum inhibitory concentration (MIC) of the isolates according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The CLSI breakpoint was used to determine antimicrobial susceptibilities, except for that of tigecycline, for which the US Food and Drug Administration (FDA) breakpoints were used. More than 99% of isolates were susceptible to vancomycin (100%), linezolid (100%), tigecycline (99.9%), and levofloxacin (99.1%). Macrolides (erythromycin, azithromycin, and clarithromycin, 67.1-69.4% susceptibility globally) and penicillin (61.7% in globally) were the drugs with more resisitance to . Penicillin-intermediate and -resistant isolates were found in 24.8% and 13.6% of isolates. was highly susceptible (>98.7%) to all antibiotics tested except for ampicillin, for which susceptibility was 76.1%. The number of drugs with the lowest susceptibility calculated in Asia were far more than other regions, with 61.5% (8 in 13 drugs) in and 70.0% (7 in 10 drugs) in , respectively. Vancomycin, linezolid, tigecycline, and levofloxacin can be used as the first choice in the empirical therapy of infection disease caused by . But macrolides and penicillin should be used prudently in treatment of the infection caused by , as well as ampicillin treat the infection caused by . Asia was the region with the most severe resistance in and .
为了解全球范围内[具体病菌名称1]和[具体病菌名称2]的流行情况，并为临床合理使用抗菌药物提供依据，作为替加环素评估与监测试验（TEST）的一部分，对2015年至2017年期间从全球150个中心获取的3929株[具体病菌名称1]和4043株[具体病菌名称2]分离株进行了替加环素及对照药物的体外活性评估。根据临床和实验室标准协会（CLSI）的指南，采用肉汤微量稀释法测定分离株的最低抑菌浓度（MIC）。除替加环素采用美国食品药品监督管理局（FDA）的折点外，CLSI折点用于确定抗菌药物敏感性。超过99%的[具体病菌名称1]分离株对万古霉素（100%）、利奈唑胺（100%）、替加环素（99.9%）和左氧氟沙星（99.1%）敏感。大环内酯类药物（红霉素、阿奇霉素和克拉霉素，全球敏感性为67.1 - 69.4%）和青霉素（全球为61.7%）是对[具体病菌名称1]耐药性较高的药物。在[具体病菌名称1]分离株中，青霉素中介和耐药分离株分别占24.8%和13.6%。[具体病菌名称2]对除氨苄西林外的所有测试抗生素高度敏感（>98.7%），氨苄西林的敏感性为76.1%。在亚洲计算出的敏感性最低的药物数量远多于其他地区，[具体病菌名称1]中为61.5%（13种药物中有8种），[具体病菌名称2]中为70.0%（10种药物中有7种）。万古霉素、利奈唑胺、替加环素和左氧氟沙星可作为由[具体病菌名称1]引起的感染性疾病经验性治疗的首选药物。但大环内酯类药物和青霉素在治疗由[具体病菌名称1]引起的感染时应谨慎使用，氨苄西林治疗由[具体病菌名称2]引起的感染时也应谨慎使用。亚洲是[具体病菌名称1]和[具体病菌名称2]耐药性最严重的地区。
